ENGN Profile
enGene Holdings Inc., via its subsidiary enGene, Inc., functions as a clinical-stage biotechnology firm specializing in the development of genetic medicines aimed at delivering therapeutics to mucosal tissues and diverse organs. Central to its portfolio is EG-70 (detalimogene voraplasmid), a leading product candidate designed as a non-viral immunotherapy targeting patients with non-muscle invasive bladder cancer, particularly those with carcinoma-in-situ (Cis) who have shown resistance to Bacillus Calmette-Guérin treatment.
Founded in 2023 and headquartered in Saint-Laurent, Canada, enGene Holdings Inc. leverages innovative genetic delivery platforms to advance therapeutic solutions that address unmet medical needs. The company's proprietary technologies are engineered to enhance the efficacy and specificity of treatments, offering promising prospects for patients suffering from various mucosal and systemic disorders.
Operatively, enGene focuses on translating cutting-edge scientific research into clinical applications, supported by a robust pipeline of novel genetic medicines. Beyond EG-70, the company continues to explore and develop additional therapeutic candidates utilizing its platform technology, positioning itself at the forefront of genetic medicine innovation.
With a commitment to rigorous scientific advancement and patient-centric innovation, enGene Holdings Inc. aims to redefine treatment paradigms across multiple therapeutic areas. Through strategic partnerships and ongoing research initiatives, the company remains dedicated to pioneering transformative therapies that improve outcomes and quality of life for patients worldwide.
|
